459 related articles for article (PubMed ID: 19238169)
1. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
[TBL] [Abstract][Full Text] [Related]
2. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.
Moul JW
Mol Urol; 2000; 4(3):267-71;discussion 273. PubMed ID: 11062383
[TBL] [Abstract][Full Text] [Related]
3. Hormonal manipulation for rising PSA after radical prostatectomy.
Bhayani SB; Andriole GL
Semin Urol Oncol; 1999 Aug; 17(3):148-53. PubMed ID: 10462318
[TBL] [Abstract][Full Text] [Related]
4. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
6. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
7. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen recurrence after definitive therapy.
Freedland SJ; Moul JW
J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
[TBL] [Abstract][Full Text] [Related]
9. [Salvage radiotherapy in rising PSA after radical prostatectomy].
Carrie C; Pommier P
Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for localized, high-risk prostate cancer.
Narayan S; Smith DC; Sandler HM
Semin Radiat Oncol; 2003 Apr; 13(2):152-7. PubMed ID: 12728444
[TBL] [Abstract][Full Text] [Related]
11. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
[TBL] [Abstract][Full Text] [Related]
12. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.
Pearce A; Choo R; Danjoux C; Morton G; Loblaw DA; Szumacher E; Cheung P; Deboer G; Chander S
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):78-83. PubMed ID: 16563657
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
14. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
15. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
RĂ¼bben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
16. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
17. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
18. [Surgical and medical treatment for localized prostate cancer].
Kawai K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
[TBL] [Abstract][Full Text] [Related]
19. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
[No Abstract] [Full Text] [Related]
20. Rising prostate-specific antigen after primary prostate cancer therapy.
Ward JF; Moul JW
Nat Clin Pract Urol; 2005 Apr; 2(4):174-82. PubMed ID: 16474760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]